Jana Care, an early stage at-home in vitro diagnostics company, and Roche Diagnostics, a global provider in medicines and diagnostics, announced a collaboration agreement for its digitally connected, blood testing platform to enable patients to self-administer critical blood tests at-home and clinicians to review the test results remotely.
Initially focused on monitoring the progression of chronic kidney disease and heart failure, the platform is designed to overcome distance and socioeconomic hurdles impeding adequate and timely detection and monitoring of disease progression and risk management, the company says.
“The addition of a world-class strategic partner such as Roche to our existing development relationships provides strong support to the company’s momentum in bringing this groundbreaking technology to market,” says Anh Hoang-Lindsay, CEO of Jana Care. “The need for improving real point-of-care testing is critical as innovation needs to keep pace with our more decentralized healthcare model.”
Chronic Kidney & Heart Disease
Health-related quality of life is substantially lower for the 37 million and 6.5 million people living with chronic kidney disease and congestive heart failure in the U.S., respectively. Regular testing is critically important to monitor disease progression and quickly respond.
Currently, key blood tests to monitor these patients in at-home settings are not available. The Jana Care-Roche collaboration would enable a more convenient approach to triaging and monitoring these patients remotely.
“We are excited to work with Jana Care’s platform technology to help empower clinicians and individuals and improve patient outcomes,” says Cristin Hubbard, global head of partnering at Roche Diagnostics. “Through this collaboration, we can gain the execution capabilities and a shared commitment to address this massive global need.”